One notable advancement in CAR T-cell therapy for the treatment of MM is the development of bb21217, an anti-BCMA CAR T-cell therapy (NCT03274219), building on the investigational therapy bb2121 [45–47]. This evidence concerns the gene TNFRSF17 and Miyoshi myopathy.